<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544293</url>
  </required_header>
  <id_info>
    <org_study_id>SAV006-05</org_study_id>
    <secondary_id>2020-001263-85</secondary_id>
    <nct_id>NCT04544293</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)</brief_title>
  <acronym>IMPALA-2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Savara Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Savara Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to&#xD;
      receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects&#xD;
      completing the 48 week placebo-controlled period will receive open-label treatment with once&#xD;
      daily inhaled molgramostim for 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, randomized, double-blind, 2-arm, parallel groups,&#xD;
      placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with&#xD;
      aPAP.&#xD;
&#xD;
      An aPAP diagnosis should be confirmed by an anti-GM-CSF auto-antibody test result, and&#xD;
      history of PAP based on either high resolution computed tomography, lung biopsy, or&#xD;
      bronchoalveolar lavage cytology, should be available.&#xD;
&#xD;
      The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment&#xD;
      period, a 48-week open-label treatment period, and a conditional 4-week safety follow-up&#xD;
      period. The maximum treatment duration will be 97 weeks and the maximum trial duration will&#xD;
      be 108 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case&#xD;
      of worsening of aPAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subject will be randomized 1:1 to treatment with inhaled molgramostim or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in percentage (%) predicted diffusing capacity of the lung for carbon monoxide (DLCO) to Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>As a measure of pulmonary gas exchange, a standardized lung function test, DLCO, will be conducted. The single-breath DLCO test will be performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percentage (%) predicted DLCO to Week 48</measure>
    <time_frame>From Baseline to Week 48</time_frame>
    <description>As a measure of pulmonary gas exchange, a standardized lung function test, DLCO, will be conducted. The single-breath DLCO test will be performed in accordance with ATS/ERS guidelines for DLCO testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in St. Georges Respiratory Questionnaire (SGRQ) Total score to Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>The SGRQ includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. The subjects will be asked to grade their current health on a 5-point scale (very poor, poor, fair, good, or very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SGRQ Activity component score to Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The SGRQ includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. The subjects will be asked to grade their current health on a 5-point scale (very poor, poor, fair, good, or very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in exercise capacity (EC), expressed as peak metabolic equivalents (METs) to Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>As a functional measure of exertional limitations related to dyspnea, EC will be assessed by an exercise treadmill test. EC will be expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved will be used to calculate peak METs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SGRQ Total score to Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The SGRQ includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. The subjects will be asked to grade their current health on a 5-point scale (very poor, poor, fair, good, or very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SGRQ Activity from baseline to Week 48</measure>
    <time_frame>From Baseline to Week 48</time_frame>
    <description>The SGRQ includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. The subjects will be asked to grade their current health on a 5-point scale (very poor, poor, fair, good, or very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EC, expressed as peak METs to Week 48</measure>
    <time_frame>From Baseline to Week 48</time_frame>
    <description>As a functional measure of exertional limitations related to dyspnea, EC will be assessed by an exercise treadmill test. EC will be expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved will be used to calculate peak METs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in alveolar-arterial oxygen difference (A-aDO2) to Week 24 (Specifically for Japan and South Korea)</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>A-aDO2 will be used as an additional measure of gas exchange.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious and non-serious adverse events</measure>
    <time_frame>From screening (6-week) until Follow-up visit (Week 100)</time_frame>
    <description>Assessment of the safety of MOL compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with positive treatment-boosted anti Granulocyte macrophage colony stimulating factor (GM-CSF) antibody titers during 24 weeks' treatment and during 48 weeks' treatment</measure>
    <time_frame>From screening (6-week) until Follow-up visit (Week 100)</time_frame>
    <description>Assessment of the safety of MOL compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Forced vital capacity (FVC)</measure>
    <time_frame>From Baseline to Weeks 24 and 48</time_frame>
    <description>Assessment of the safety of MOL compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>From Baseline to Weeks 24 and 48</time_frame>
    <description>Assessment of the safety of MOL compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QT interval corrected by Fridericia (QTcF)</measure>
    <time_frame>From Baseline to Weeks 4 and 24</time_frame>
    <description>Assessment of the safety of MOL compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Autoimmune Pulmonary Alveolar Proteinosis</condition>
  <arm_group>
    <arm_group_label>Molgramostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molgramostim</intervention_name>
    <description>Molgramostim 300 µg nebulizer solution</description>
    <arm_group_label>Molgramostim</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in&#xD;
             Japan).&#xD;
&#xD;
          2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.&#xD;
&#xD;
          3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL)&#xD;
             cytology, or a high-resolution computed tomogram (HRCT) of the chest.&#xD;
&#xD;
          4. DLCO 70% predicted or lower at the screening and baseline visits.&#xD;
&#xD;
          5. Change in % predicted DLCO of &lt;15% points during the screening period.&#xD;
&#xD;
          6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak&#xD;
             MET ≤8).&#xD;
&#xD;
          7. Willing and able to come off supplemental oxygen use prior to and during the treadmill&#xD;
             exercise test, the DLCO assessment, and the arterial blood gas sampling.&#xD;
&#xD;
          8. Resting SpO2 &gt;85% during 15 minutes without use of supplemental oxygen at the&#xD;
             screening visits.&#xD;
&#xD;
          9. Male or female&#xD;
&#xD;
         10. Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
               1. Male subjects: Males agreeing to use condoms during and until 30 days after last&#xD;
                  dose of trial treatment, or males having a female partner who is using adequate&#xD;
                  contraception as described below.&#xD;
&#xD;
               2. Female subjects: Females who have been post-menopausal for &gt;1 year, or females of&#xD;
                  childbearing potential after a confirmed menstrual period using a highly&#xD;
                  efficient method of contraception (i.e. a method with &lt;1% failure rate such as&#xD;
                  combined hormonal contraception, progesterone-only hormonal contraception,&#xD;
                  intrauterine device, intrauterine hormone-releasing system, bilateral tubal&#xD;
                  occlusion, vasectomized partner, sexual abstinence*), during and until 30 days&#xD;
                  after last dose of trial treatment. Females of childbearing potential must have a&#xD;
                  negative serum pregnancy test at the screening visits, and a negative urine&#xD;
                  pregnancy test at Baseline visit (Visit 3) and must not be lactating.&#xD;
&#xD;
         11. Capable of giving signed informed consent as described in Appendix 1 which includes&#xD;
             compliance with the requirements and restrictions listed in the informed consent form&#xD;
             (ICF) and in this protocol.&#xD;
&#xD;
         12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other trial procedures specified in the protocol as judged by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant&#xD;
             production.&#xD;
&#xD;
          2. WLL performed within 3 months prior to baseline.&#xD;
&#xD;
          3. Requirement for WLL at screening or baseline.&#xD;
&#xD;
          4. GM-CSF treatment within 6 months prior to baseline.&#xD;
&#xD;
          5. Treatment with rituximab within 6 months prior to baseline.&#xD;
&#xD;
          6. Treatment with plasmapheresis within 6 weeks prior to baseline.&#xD;
&#xD;
          7. Treatment with any investigational medicinal product within 5 half-lives or 3 months&#xD;
             (whichever is longer) prior to baseline.&#xD;
&#xD;
          8. Previously randomized in this trial.&#xD;
&#xD;
          9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer&#xD;
             solution.&#xD;
&#xD;
         10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g.&#xD;
             more than 10 mg/day systemic prednisolone) immunosuppression.&#xD;
&#xD;
         11. Previous experience of severe and unexplained side-effects during aerosol delivery of&#xD;
             any kind of medicinal product.&#xD;
&#xD;
         12. History of, or present, myeloproliferative disease or leukemia.&#xD;
&#xD;
         13. Apparent pre-existing concurrent pulmonary fibrosis.&#xD;
&#xD;
         14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.&#xD;
&#xD;
         15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect&#xD;
             the efficacy evaluation in the trial.&#xD;
&#xD;
         16. Physical disability or other condition that precludes safe and adequate exercise&#xD;
             testing.&#xD;
&#xD;
         17. Any other serious medical condition which in the opinion of the Investigator would&#xD;
             make the subject unsuitable for the trial.&#xD;
&#xD;
         18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For&#xD;
             France only: including as further defined by French Health Code L-1121-5.&#xD;
&#xD;
         19. Any subject considered to be &quot;vulnerable&quot; on account of, e.g., mental or physical&#xD;
             disability, socio-economic situation, or subjects deprived of their liberty. For&#xD;
             France only: including as further defined by French Health Code L1121-8-1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Trapnell, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dhaval Desai, MD</last_name>
    <phone>+1 (512) 851-1373</phone>
    <email>info@savarapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Badrul Chowdhury</last_name>
    <phone>+1 (512) 614-1848</phone>
    <email>info@savarapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Meena</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tisha Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Downey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Puchalski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Ataya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Berkowitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Dilling</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashutosh Sachdeva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington U. in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Anderson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Bergin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children'S Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Trapnell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Tolle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman School of Medicine - Pulmonology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David DiBardino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Donahoe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muhanned Abu-Hijleh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Troy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wheatley John</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <state>Région De Bruxelles-Capitale</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Bondue</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg - Pneumologie</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wim Wuyts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul MacEachern</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.Institute of Cardiology and Respirology of Quebec</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Fortin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Cottin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Jouneau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kreuter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Donaustauf</name>
      <address>
        <city>Donaustauf</city>
        <state>Bayern</state>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Blaas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Muenchen-Gauting</name>
      <address>
        <city>Muenchen-Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Gesierich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Westdeutsches Lungenzentrum</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>cormac Bonella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laikon General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Papiris Spyridon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DO4 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cormac McCarthy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Mariani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaidô</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaru 雅 Suzuki 鈴木</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomohisa 智尚 Baba 馬場</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital - Respiratory Tract Medicine</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadahisa 忠久 Numakura 沼倉</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-Chuo Chest medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshikazu 義一 Inoue 井上</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haruyuki 晴之 Ishii 石井</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital - Respiratory Medicine</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abe 安部 Mitsuhiro 光洋 Abe 安部</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Nagakute</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Satoru 理 Ito 伊藤</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Red Cross Hospital</name>
      <address>
        <city>Saitama</city>
        <zip>330-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiichi 圭一 Akasaka 赤坂</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital - Yonsei University Health System - Pulmonary</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moo Suk 무석 Park 박</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Man Pyo 만표 Chung 정</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunmi 선미 Choi 최</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Woo Song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Veltkamp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Gruzlicy i Chorob Pluc</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justyna Fijolek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulido Valente</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Salgado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São João</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Morais</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul de Pneumoftiziologie &quot;Marius Nasta&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florin Mihaltan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GOU VPO St.Petersburg State Medical University &quot;I.P.Pavlova&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikhail Mikhailovich Ilkovich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Molina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Hospital - Department of Pulmonology</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nesrin Mogulkoc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Sciences University Gulhane Training and Research Hos</name>
      <address>
        <city>Ankara</city>
        <zip>6010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nesrin Öcal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yedikule Chest Disease and Surgery Traning and Research Hosp</name>
      <address>
        <city>Istanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erdogan Cetinkaya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Kokosi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

